Description
BSE notifies listing and trading permission for 6,44,360 new equity shares of Fredun Pharmaceuticals Limited issued on preferential basis to non-promoters, effective March 4, 2026. Shares are subject to lock-in until September 15, 2026.
Summary
BSE has notified trading members that 6,44,360 new equity shares of Fredun Pharmaceuticals Limited (Scrip Code: 539730, ISIN: INE194R01017) are listed and permitted to trade on the Exchange effective Wednesday, March 4, 2026. These shares were issued on a preferential basis to non-promoters at an issue price of Rs. 1,250/- per share (face value Rs. 10/- with a premium of Rs. 1,240/-).
Key Points
- Scrip Code: 539730 | ISIN: INE194R01017
- Number of Shares: 6,44,360 equity shares
- Face Value: Rs. 10/- per share
- Issue Price: Rs. 1,250/- per share (premium of Rs. 1,240/-)
- Allotment Type: Preferential basis to non-promoters
- Distribution Numbers: 4765963 to 5410322
- Date of Allotment: December 29, 2025
- Trading Effective From: Wednesday, March 4, 2026
- Ranking: Pari-passu with existing equity shares of the company
Regulatory Changes
No new regulatory changes introduced. This is a standard listing notice under BSE’s framework for admission of new securities to trading.
Compliance Requirements
- Trading members are informed to update their systems to reflect the new securities available for trading from March 4, 2026.
- All 6,44,360 shares (Dist. Nos. 4765963 to 5410322) are subject to a lock-in period and cannot be traded until the lock-in expiry date.
Important Dates
| Event | Date |
|---|---|
| Date of Allotment | December 29, 2025 |
| Trading Commencement | March 4, 2026 |
| Lock-in Expiry | September 15, 2026 |
Impact Assessment
The listing adds 6,44,360 shares to the tradeable equity base of Fredun Pharmaceuticals Limited; however, the entire new allotment is subject to lock-in until September 15, 2026, meaning there is no immediate increase in free-float. The preferential allotment at Rs. 1,250/- per share signals non-promoter investor interest. Post lock-in expiry, the release of these shares could modestly increase supply in the market. Overall market impact is limited to participants tracking this specific scrip.
Impact Justification
Routine preferential allotment listing notice affecting a specific mid-cap pharma scrip; introduces new tradeable shares but with a lock-in constraint that limits near-term float impact.